AbbVie Inc

AbbVie’s Medicaid pricing deal, U.S. R&D investment and exclusive antibody license set a new strategy for U.S. market dominance amid patent cliffs and fierce competition.

AbbVie faces a 12% Humira decline but plans 12‑year growth via biosimilar‑ready market‑access, new indications, RWE deals, and precision‑medicine M&A.

AbbVie’s Q4 earnings dip amid heavy R&D spend—no Revolution Medicines deal—signals a long‑term focus on immunology, oncology, and new biologics, reshaping 2025 forecasts and patient care strategies.

AbbVie’s JPMC strategy: high‑margin neuromuscular growth, value‑based pricing, and digital platforms to boost access, reduce costs, and outpace the 14% CAGR market.

AbbVie’s Q3 miss yet raised guidance, dividend hike, and drug‑price talks show how a pharma giant balances earnings, returns and regulation.

AbbVie’s recent analyst upgrades spotlight its strong pipeline, solid cash flow and disciplined capital allocation—making the biotech stock a compelling, risk‑adjusted growth opportunity.

AbbVie refines its chronic inflammation partnership with OSE Immunotherapeutics, shifting Phase‑1 duties and boosting ABBV‑230’s development while retaining long‑term equity and regulatory control.

AbbVie boosts Skyrizi advertising, outpacing J&J’s Tremfya, and sponsors a high‑profile ESMO Asia oncology symposium—showing strategic focus on psoriasis, ovarian cancer ADCs, and expanding dermatologic research.

AbbVie’s latest migraine and immunology data reveal how the company plans to win EU payers, beat CGRP rivals, and protect revenue before Humira’s patent ends.

AbbVie’s new atogepant data and protein‑degradation pipeline highlight its bid to dominate migraine and unlock untapped markets, while it navigates generic threats to Restasis and expands its precision‑medicine portfolio.